Paroxysmal Nocturnal Hemoglobinuria clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
open to eligible people ages 18 years and up
This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan
Orange, California and other locations
Our lead scientists for Paroxysmal Nocturnal Hemoglobinuria research studies include Zahra Pakbaz.
Last updated: